137 related articles for article (PubMed ID: 12559501)
1. Clinical-MRI correlations in the secondary progressive phase of MS: lessons from the treatment trials.
Clanet M; Cassol E; Manelfe C; Berry I
J Neurol Sci; 2003 Feb; 206(2):139-44. PubMed ID: 12559501
[TBL] [Abstract][Full Text] [Related]
2. Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis.
Sormani MP; Stubinski B; Cornelisse P; Rocak S; Li D; De Stefano N
Mult Scler; 2011 May; 17(5):541-9. PubMed ID: 21148262
[TBL] [Abstract][Full Text] [Related]
3. [Beta-interferon clinical trials using MRI in patients with multiple sclerosis].
Lebrun C
Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 1):761-7. PubMed ID: 11677396
[TBL] [Abstract][Full Text] [Related]
4. Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS.
Molyneux PD; Barker GJ; Barkhof F; Beckmann K; Dahlke F; Filippi M; Ghazi M; Hahn D; MacManus D; Polman C; Pozzilli C; Kappos L; Thompson AJ; Wagner K; Yousry T; Miller DH;
Neurology; 2001 Dec; 57(12):2191-7. PubMed ID: 11756596
[TBL] [Abstract][Full Text] [Related]
5. MRI lesion loads and disability relationships in MS: more similar than different?
Wolinsky JS
Neurology; 2009 Nov; 73(19):1524-5. PubMed ID: 19828867
[No Abstract] [Full Text] [Related]
6. Spotlight on Interferon-beta-1b in relapsing-remitting and secondary progressive multiple sclerosis.
McCormack PL; Scott LJ
BioDrugs; 2004; 18(5):343-7. PubMed ID: 15377176
[TBL] [Abstract][Full Text] [Related]
7. Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis.
McCormack PL; Scott LJ
CNS Drugs; 2004; 18(8):521-46. PubMed ID: 15182221
[TBL] [Abstract][Full Text] [Related]
8. [Immunologic therapy for secondary and primary progressive multiple sclerosis].
Ozawa K
Nihon Rinsho; 2003 Aug; 61(8):1449-54. PubMed ID: 12962037
[TBL] [Abstract][Full Text] [Related]
9. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
Sormani MP; Rovaris M; Comi G; Filippi M
Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
[TBL] [Abstract][Full Text] [Related]
10. T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment.
Barkhof F; van Waesberghe JH; Filippi M; Yousry T; Miller DH; Hahn D; Thompson AJ; Kappos L; Brex P; Pozzilli C; Polman CH;
Brain; 2001 Jul; 124(Pt 7):1396-402. PubMed ID: 11408334
[TBL] [Abstract][Full Text] [Related]
11. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials.
Bates D
Neurology; 2011 Jan; 76(1 Suppl 1):S14-25. PubMed ID: 21205678
[TBL] [Abstract][Full Text] [Related]
12. Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis.
van Walderveen MA; Lycklama A Nijeholt GJ; Adèr HJ; Jongen PJ; Polman CH; Castelijns JA; Barkhof F
Arch Neurol; 2001 Jan; 58(1):76-81. PubMed ID: 11176939
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b.
Giovannoni G
Neurology; 2003 Oct; 61(7):1025; author reply 1025. PubMed ID: 14557596
[No Abstract] [Full Text] [Related]
14. [Secondary progressive multiple sclerosis in childhood--interferon beta 1b treatment].
Higurashi N; Hamano S; Eto Y
No To Hattatsu; 2006 May; 38(3):209-13. PubMed ID: 16715936
[TBL] [Abstract][Full Text] [Related]
15. Interferon beta for secondary progressive multiple sclerosis.
La Mantia L; Vacchi L; Di Pietrantonj C; Ebers G; Rovaris M; Fredrikson S; Filippini G
Cochrane Database Syst Rev; 2012 Jan; 1():CD005181. PubMed ID: 22258960
[TBL] [Abstract][Full Text] [Related]
16. MRI-clinical correlations in the primary progressive course of MS: new insights into the disease pathophysiology from the application of magnetization transfer, diffusion tensor, and functional MRI.
Filippi M
J Neurol Sci; 2003 Feb; 206(2):157-64. PubMed ID: 12559504
[TBL] [Abstract][Full Text] [Related]
17. Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years.
Turner B; Lin X; Calmon G; Roberts N; Blumhardt LD
Mult Scler; 2003 Feb; 9(1):21-7. PubMed ID: 12617263
[TBL] [Abstract][Full Text] [Related]
18. MRI and assessment of treatment in multiple sclerosis.
Miller DH; Thompson AJ; Kappos L
Brain; 2001 May; 124(Pt 5):1052-3. PubMed ID: 11335707
[No Abstract] [Full Text] [Related]
19. [Primary progressive multiple sclerosis].
Brieva L; Río J; Montalbán X
Rev Neurol; 2002 Dec 1-15; 35(11):1074-80. PubMed ID: 12497315
[TBL] [Abstract][Full Text] [Related]
20. Primary progressive multiple sclerosis.
Montalban X
Curr Opin Neurol; 2005 Jun; 18(3):261-6. PubMed ID: 15891409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
